DEF: Nektar Therapeutics 2026 Annual Meeting Proxy Statement

Nektar Therapeutics has issued its 2026 proxy statement, seeking shareholder approval for director election, an increase in equity plan shares, and executive compensation.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 4, 2026, via live webcast.
• Proposal 1: Election of Howard W. Robin as a Class I director for a term expiring in 2029.
• Proposal 2: Approval of an amendment to the 2017 Performance Incentive Plan to increase authorized shares by 3,000,000.
• Proposal 3: Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026.
• Proposal 4: Non-binding advisory vote on executive compensation (say-on-pay).
• Record date for voting is April 6, 2026, with 29,679,647 shares outstanding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a standard governance filing; while the company has achieved positive clinical milestones, the request for additional equity shares and the history of cancelled performance-based awards reflect the inherent risks and volatility of the business.

Positives

• Positive topline results from Phase 2b REZOLVE-AD trial in atopic dermatitis.
• Proof-of-concept established for rezpegaldesleukin in severe-to-very-severe alopecia areata.
• FDA Fast Track designation granted for rezpegaldesleukin in two indications.
• Strengthened financial position through public offerings in 2025 and 2026, raising significant capital.
• Successful collaboration established with TrialNet for type 1 diabetes research.

Negatives

• Failure to achieve specific pre-defined quantitative business financial goals in 2025.
• Termination of bempegaldesleukin development program in 2022, leading to cancellation of related performance-based equity grants.
• High volatility in stock price and historical underperformance relative to the Nasdaq Biotechnology Index for certain performance-based equity awards.

Risks

• Clinical development risks, including the potential for failure in Phase 3 trials.
• Dependence on the success of the lead drug candidate, rezpegaldesleukin.
• Need for continued capital to fund research and clinical development activities.
• Intense competition in the biopharmaceutical industry.
• Potential for future stock price volatility.

Future Outlook

The company intends to initiate Phase 3 studies of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in mid-2026 and continue advancing its pipeline of drug candidates.

Management Comments

• The board believes that the approval of the amendment to the 2017 Plan is instrumental to the company's continued success and ability to execute strategic priorities.
• The company believes that incentives and stock-based awards motivate employees to achieve company-wide objectives and align individual performance with the success of the company.

Industry Context

StockSavvy.ai notes that Nektar Therapeutics is navigating the typical challenges of a clinical-stage biopharmaceutical company, focusing heavily on clinical data catalysts to drive valuation while managing dilution through equity plan expansions.

Comparison to Industry Standards

• The company utilizes a peer group of pre-commercial biopharmaceutical companies with market capitalizations between $400 million and $4 billion.
• Executive compensation practices are benchmarked against industry peers to ensure competitiveness in the San Francisco Bay Area talent market.

Corporate Governance

Related Party Transactions

• Consulting agreement with FLG Partners, LLC for the services of Interim CFO Sandra Gardiner, for which $686,400 was paid in 2025.

Stakeholder Impact

• Shareholders are asked to vote on proposals that will impact equity dilution and executive compensation structures.
• Employees and directors are eligible for awards under the proposed amended equity plan.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 4, 2026.
• Initiate Phase 3 studies of rezpegaldesleukin in mid-2026.
• File final voting results in a Form 8-K within four business days after the meeting.

Key Dates

Keywords

Nektar Therapeutics, Proxy Statement, Biotechnology, Rezpegaldesleukin, Clinical Trials, Executive Compensation, Equity Incentive Plan